U.S. pharma huge copyright scrapped two experimental weight loss products very last calendar year—a after-each day capsule, lotiglipron, because of elevated liver enzymes as well as a twice-everyday tablet, danuglipron, resulting from potent Uncomfortable side effects—but CEO Albert Bourla has said the company is set to “play and win” withi